deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06811272

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

A Phase 2 Study of Outpatient Epcoritamab as Second Line Therapy in Non-Transplant Eligible Relapsed/Refractory Large B-cell Lymphoma

Sponsor: Genmab

Conditions Refractory Large B-cell Lymphoma Relapsed Large B-cell Lymphoma
Interventions Epcoritamab
Updated 3 times since 2025 Last updated: Feb 22, 2026 Started: Jun 5, 2025 Primary completion: Oct 1, 2026 Completion: Oct 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Refractory Large B-cell Lymphoma and Relapsed Large B-cell Lymphoma and is currently actively recruiting participants. Genmab leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2025 – ~Nov 2025 · 8 months · monthly snapshotNot Yet Recruiting~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshotRecruiting~Feb 2026 – present · 6 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Mar 2025 — Nov 2025 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genmab
  • Massachusetts General Hospital
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations